Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing. He wasn’t expecting a fall during an ice storm to lead to a cancer diagnosis. But ...

A case study details the cytological and histological features of fibrin-assisted diffuse large B-cell lymphoma in a patient with no clinical symptoms, highlighting the diagnostic challenges of this ...

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL). A study of 32 clinical samples from ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to epcoritamab-bysp for treatment of adults with relapsed or refractory ...

In the article that accompanies this editorial, Bartlett et al 11 present the results of ECHELON-3, a phase III trial comparing brentuximab vedotin + lenalidomide + rituximab (BV + Len + R) with ...

Intravascular large B-cell lymphoma (IVLBCL) is a very rare, aggressive non-Hodgkin’s lymphoma. With IVLBCL, lymphoma cells build up in small blood vessels, which can block blood flow and harm organs.

"Typically, patients will present with motor weakness, sensory deficits, and pain in nerve sites affected by NL. The most common nerve sites include the cauda equina nerves, the brachial plexus, the ...